share_log

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

BioLife Solutions將於2024年5月9日公佈2024年第一季度財務業績和業務最新情況
PR Newswire ·  04/30 16:12

BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update.

華盛頓州博塞爾,2024年4月30日 /PRNewswire/ — 爲細胞和基因療法(“CGT”)及更廣泛的生物製藥市場提供定義類別的生物生產工具和服務的領先供應商BioLife Solutions, Inc.(納斯達克股票代碼:BLFS)今天宣佈,公司2024年第一季度財務業績將在2024年5月9日星期四收盤後公佈。該公司將在美國東部時間當天下午 4:30(太平洋時間下午 1:30)舉辦電話會議和網絡直播。管理層將概述公司的財務業績,並提供一般業務最新情況。

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at In addition, the conference call will be accessible by dialing toll-free 1-877-346-6112 or 1-848-280-6350 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on for 90 days.

要觀看網絡直播,請登錄BioLife Solutions網站的投資者關係頁面,此外,國際來電者可撥打免費電話1-877-346-6112或1-848-280-6350進行電話會議。網絡直播重播將在電話會議結束大約兩小時後提供,並將存檔90天。

About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X.

關於 BioLife 解決方案
BioLife Solutions是爲細胞和基因療法(CGT)和更廣泛的生物製藥市場提供定義類別的生物生產工具和服務的領先供應商。我們的專業知識通過提供在收集、開發、儲存和分發過程中保持生物材料健康和功能的解決方案,促進新療法的商業化。欲了解更多信息,請訪問或關注 LinkedIn 和 X 上的 BioLife

Media & Investor Relations

媒體與投資者關係

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
[email protected]

在公司
特洛伊·威奇特曼
首席財務官
(425) 402-1400
[電子郵件保護]

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
[email protected]

投資者
LHA 投資者關係
喬迪·凱恩
(310) 691-7100
[電子郵件保護]

SOURCE BioLife Solutions, Inc.

來源 Biolife Solutions, Inc.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論